# A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

> **NCT06045910** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cancer Research UK** · enrollment: 84 (estimated)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Follicular
- Lymphoma, B-Cell
- Large B-cell Lymphoma

## Interventions

- **DRUG:** ALETA-001

## Key facts

- **NCT ID:** NCT06045910
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-07
- **Primary completion:** 2028-02
- **Final completion:** 2029-12-21
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06045910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06045910, "A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06045910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*